Ampio Pharmaceuticals Inc.

3.68+0.0600+1.66%Vol 5.93K1Y Perf 6 098.63%
Oct 3rd, 2023 15:59 DELAYED
BID3.68 ASK3.74
Open3.66 Previous Close3.62
Pre-Market- After-Market-
 - -  - -%
Target Price
2.50 
Analyst Rating
— 0.00
Potential %
-32.07 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
2.14 
Earnings Rating
Buy
Market Cap2.78M 
Earnings Date
13th Nov 2023
Alpha-0.04 Standard Deviation0.26
Beta1.78 

Today's Price Range

3.653.94

52W Range

3.3518.60

5 Year PE Ratio Range

-5.301.70

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-3.00%
1 Month
1 709.10%
3 Months
1 439.12%
6 Months
1 535.79%
1 Year
6 098.63%
3 Years
314.09%
5 Years
596.15%
10 Years
-52.18%

TickerPriceChg.Chg.%
AMPE3.680.06001.66
AAPL172.40-1.3500-0.78
GOOG133.30-1.8700-1.38
MSFT313.39-8.4100-2.61
XOM115.830.20000.17
WFC38.67-0.9400-2.37
JNJ155.340.19000.12
FB196.640.99000.51
GE107.76-1.0300-0.95
JPM142.71-1.0600-0.74
Financial StrengthValueIndustryS&P 500US Markets
4.30
4.70
0.03
0.05
-
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
-
-
-
-
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2024--0.09-
Q03 2022--0.50-
Q02 2022-0.30-0.300.00
Q01 2022-0.30-0.45-50.00
Q04 2021-0.30-0.60-100.00
Q03 2021-0.30-0.300.00
Q02 2021-0.30-0.300.00
Q01 2021-0.02-0.020.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.020.00-
9/2022 QR-0.020.00-
12/2022 FY-0.0811.11Positive
12/2023 FY-0.080.00-
Next Report Date13th Nov 2023
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume5.93K
Shares Outstanding755
Shares Float689.27K
Trades Count214
Dollar Volume22.20K
Avg. Volume197.26K
Avg. Weekly Volume13.37K
Avg. Monthly Volume126.20K
Avg. Quarterly Volume452.21K

Ampio Pharmaceuticals Inc. (AMEX: AMPE) stock closed at 3.62 per share at the end of the most recent trading day (a -0.55% change compared to the prior day closing price) with a volume of 7.88K shares and market capitalization of 2.78M. Is a component of indices and it is traded on AMEX exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 23 people. Ampio Pharmaceuticals Inc. CEO is Michael E. Macaluso.

The one-year performance of Ampio Pharmaceuticals Inc. stock is 6098.63%, while year-to-date (YTD) performance is 1507.46%. AMPE stock has a five-year performance of 596.15%. Its 52-week range is between 3.354 and 18.6, which gives AMPE stock a 52-week price range ratio of 2.14%

Ampio Pharmaceuticals Inc. currently has a PE ratio of -0.20, a price-to-book (PB) ratio of 0.32, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -98.48%, a ROC of -124.68% and a ROE of -130.71%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Ampio Pharmaceuticals Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Ampio Pharmaceuticals Inc.’s next earnings report date is 13th Nov 2023.

The consensus rating of Wall Street analysts for Ampio Pharmaceuticals Inc. is (0), with a target price of $2.5, which is -32.07% compared to the current price. The earnings rating for Ampio Pharmaceuticals Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Ampio Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Ampio Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 23.86, ATR14 : 0.34, CCI20 : 22.88, Chaikin Money Flow : 0.25, MACD : 0.79, Money Flow Index : 57.39, ROC : -13.19, RSI : 69.95, STOCH (14,3) : 0.63, STOCH RSI : 0.00, UO : 22.05, Williams %R : -99.37), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Ampio Pharmaceuticals Inc. in the last 12-months were: David R. Stevens (Buy at a value of $15 400), J. Kevin Buchi (Buy at a value of $39 255), Martino Michael (Buy at a value of $22 298)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
1 (100.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
0 (0.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating-
0.00
-
0.00
Strong Buy
1.00

Ampio Pharmaceuticals Inc.

Ampio Pharmaceuticals Inc is a biopharmaceutical company. The company focused primarily on developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process and decreasing vascular permeability. Ampio's leading product candidates are Ampion and Optina. It is currently conducting the second pivotal clinical trial in the United States for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee.

CEO: Michael E. Macaluso

Telephone: +1 720 437-6500

Address: 373 Inverness Parkway, Englewood 80112, CO, US

Number of employees: 23

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

60%40%

Bearish Bullish

63%37%

 

News

Stocktwits